Risankizumab (BI 655066) is a humanized IgG monoclonal antibody (Kd <10 pM) targeting the IL-23 p19 subunit. It inhibits IL-17 production induced by human IL-23 in mouse splenocytes with an IC50 value of 2 pM. Risankizumab is used for the prevention and treatment of immune and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis.
Purity:
95.30%
CAS Number:
[1612838-76-2]
Target:
Interleukin|||IL Receptor
T76778
T76778
* VAT and and shipping costs not included. Errors and price changes excepted
